1,258.00p+39.00 (+3.20%)06 Jul 2022, 18:01
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Abcam PLC Fundamentals

Company NameAbcam PLCLast Updated2022-07-06
Shares in Issue228.968 mMarket Cap£2.88 bn
PE Ratio185.19Dividend per Share0
Dividend Yield0Dividend Cover0
EPS£0.08EPS Growth (%)-0.26
PEG0DPS Growth (%)0
Debt Ratio0.1340Debt Equity Ratio0.1613
Asset Equity Ratio1.2990Cash Equity Ratio0.3465
Quick Ratio3.9806Current Ratio4.78
Price To Book Value4.2535ROCE0

Abcam PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Abcam PLC Company Financials

Tangible Assets£161.70 m£164.70 m£37.10 m
Intangible Assets£599.00 m£345.10 m£225.50 m
Investments£3.50 m£7.00 m£800,000.00
Total Fixed Assets£774.60 m£530.50 m£272.80 m
Stocks£58.20 m£40.70 m£36.00 m
Debtors£42.10 m£39.70 m£43.10 m
Cash & Equivalents£95.10 m£187.30 m£87.10 m
Other Assets£10.40 m£13.70 m£9.40 m
Total Assets£986.10 m£809.30 m£444.60 m
Creditors within 1 year£187.20 m£159.60 m£45.30 m
Creditors after 1 year£142.80 m£148.80 m£16.20 m
Other Liabilities000
Total Liabilities£330.00 m£308.40 m£61.50 m
Net assets£656.10 m£500.90 m£383.10 m
Called up share capital£500,000.00£400,000.00£400,000.00
Share Premium£268.30 m£138.20 m£27.00 m
Profit / Loss£20.30 m£8.30 m£55.60 m
Other Equity£656.10 m£500.90 m£383.10 m
Preference & Minorities000
Total Capital Employed£656.10 m£500.90 m£383.10 m
Debt Ratio£0.1900
Assets / Equity1.29901.29901.2990
Cash / Equity0.34650.34650.3465
Cash Flow202120202019
Cash from operating activities£96.20 m£63.00 m£69.30 m
Cashflow before financing£222.60 m£247.60 m£44.60 m
Increase in Cash-£91.10 m£99.50 m-£4.40 m
Turnover£462.90 m£260.00 m£259.90 m
Cost of sales£133.70 m£79.80 m£76.70 m
Gross Profit£329.20 m£180.20 m£183.20 m
Operating Profit£24.40 m£10.40 m£55.30 m
Pre-Tax profit£20.30 m£8.30 m£55.60 m

Abcam PLC Company Background

ActivitiesAbcam PLC is a biotechnology company that develops and provides antibodies to life science research and clinical communities. The company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders. Abcam's focused on broadening its product range, improving speed to market, and accessing underpenetrated consumer groups in its markets. The company also selectively pursues partnerships and acquisitions.
Latest Interim Date13 Sep 2021
Latest Fiscal Year End Date14 Mar 2022

Abcam PLC Directors

2009-11-03Mr. Timothy George DyeNon-Executive Director
2021-08-13Dr. Jonathan Simon MilnerNon-Executive Director,Deputy Chairman
2016-09-26Mr. Jeffrey Michel IliffeExecutive Director,Chief Financial Officer
2011-08-09Mr. Mark John Alexander WebsterNon-Executive Director
2020-09-18Lady Louise Alexandra Virginia Charlotte Patten of WincantonIndependent Director
2014-11-03Mr. Michael RedmondNon-Executive Director,Chairman
2020-09-18Mr. Giles Francis Bertram KerrIndependent Director
2014-11-03Mr. Peter Stephen KeenNon-Executive Director
2012-10-22Professor Tony KouzaridesNon-Executive Director
2017-09-22Dr. David James WarwickExecutive Director,Chief Operating Officer
2020-09-18Mr. Peter Vance AllenChairman of the Board
2016-10-31Dr. Anthony Francis MartinNon-Executive Director
2018-09-24Mr. Murray Edwin HennessyExecutive Director,Chief Executive Officer
2009-09-16Dr. David Douglas Cleevely PhD,FIET,FREngNon-Executive Director,Chairman
2011-08-09Dr. Edward William Eddie Powell PhD,FCAExecutive Director,Finance Director
2016-10-31Mr. Michael Alexander Nunes RossNon-Executive Director
2019-11-13Ms. Susan Elizabeth HarrisNon-Executive Director
2020-02-03Mr. Gavin Hilary James Wood Executive Director,Chief Financial Officer
2021-11-12Mr. Alan Thomas HirzelChief Executive Officer and Director
2020-09-18Ms. Mara Glickman AspinallIndependent Director
2019-10-03Ms. Suzanne SmithLegal Officer and Company Secretary
2022-03-17Mr. Michael Shaun BaldockChief Financial Officer and Director

Abcam PLC Contact Details

Company NameAbcam PLC
AddressMilton Road, 330 Cambridge Science Park, Cambridge, CB4 0FL
Telephone+44 01223 696000

Abcam PLC Advisors

RegistrarEquiniti Ltd.
Phone+44 1214157082
Financial PR AdviserFTI Consulting Inc
Phone+44 2037271000
Fax+44 2037271007
Nominated AdviserJ.P. Morgan Cazenove
Phone+44 2077424000
StockbrokerJ.P. Morgan Cazenove Ltd
Phone+44 2077424000
Remuneration ConsultantDeloitte & Touche LLP
Phone+44 2079363000
Fax+44 2075831198
AuditorPricewaterhouseCoopers LLP
Phone+44 1223460055
Fax+44 1223552336
BankNational Westminster Bank PLC
SolicitorEversheds Sutherland
Phone+44 2079194500
Fax+44 2079194919